KZR-616

Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases.


Cat. No.: EX-A6921	Purity: >98%

	Chemical structure of KZR-616

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	get quote	Inquire
250mg	get quote	Inquire
500mg	get quote	Inquire
1g	get quote	Inquire
2g	get quote	Inquire
5g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Zetomipzomib
CAS No.	1629677-75-3
Purity	>98%
Formula	C30H42N4O8
Mol Weight	586.6765
Color	White to off-white
State	solid powder
Solubility	Soluble in DMSO? 50 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder 4°C, sealed storage, away from moisture; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Johnson HWB, et al. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl) [2]. Muchamuel T, et al. FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases 2018;77:685. [3]. Xi J, et al. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem. 2019;182:111646.
CoA	CoA of KZR-616


		Search